Adipokines play a significant role in the pathogenesis of NASH and may serve as noninvasive diagnostic markers and future therapeutic targets.
Answers are grounded in this paper and cite their sources.
Should not yet change NAFLD management; leaves open adipokines as diagnostic markers and targets pending prospective validation.
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and can vary from benign steatosis to end-stage liver disease. The pathogenesis of non-alcoholic steatohepatitis (NASH) is currently thought to involve a multiple-hit process with the first hit being the accumulation of liver fat which is followed by the development of necroinflammation and fibrosis. There is mounting evidence that cytokines secreted from adipose tissue, namely, adipokines, are implicated in the pathogenesis and progression of NAFLD. In the current review, we explore the role of these adipokines, particularly leptin, adiponectin, resistin, tumor necrosis factor-a, and interleukin-6 in NASH, as elucidated in experimental models and clinical practice. We also comment on their potential use as noninvasive markers for differentiating simple fatty liver from NASH as well as on their potential future therapeutic role in patients with NASH.
No takes yet. Share an insight, caveat, or question.
Tsochatzis et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: